Highlights Senhwa Biosciences, Inc.

Equities

6492

TW0006492002

End-of-day quote Taipei Exchange Other stock markets 03:30:00 04/06/2024 am IST			5-day change	1st Jan Change
41.8 ^TWD	+0.36%		-1.18%	-17.88%

15/05	Senhwa Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI
20/03	Senhwa Biosciences Announces First Patient Dosed in the Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia Associated with Viral Infection in Taiwan	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Senhwa Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05	CI
Senhwa Biosciences Announces First Patient Dosed in the Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia Associated with Viral Infection in Taiwan	20/03	CI
Senhwa Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	14/03	CI
Senhwa Biosciences, Inc. Decides to Early Terminate the Phase II study of Silmitasertib to treat hospitalized patients with COVID-19	05/01	CI
Senhwa Biosciences Receives Taiwan FDA IND Approval for Phase Ii Study of Silmitasertib in Patients with Community-Acquired Pneumonia Associated with Viral Infection	26/12	CI
Senhwa Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	10/11	CI
Senhwa Biosciences, Inc. Announces First Patient Successfully Dosed in Taiwan Phase II Study of Silmitasertib in Hospitalized Adults with COVID-19	09/11	CI
Senhwa Biosciences Announces Investigational New Drug Submission to U.S. Food and Drug Administration for Phase II Study of Silmitasertib in Patients with Community-Acquired Pneumonia Associated with Viral Infection	19/23/19	CI
Senhwa Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/23/10	CI
Senhwa Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23/23/23	CI
Senhwa Biosciences Receives Taiwan Fda Ind Approval for Phase II Study of Silmitasertib in Patients with Moderate to Severe Covid-19	28/23/28	CI
Senhwa Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	30/23/30	CI
Senhwa Biosciences, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	11/22/11	CI
Senhwa Biosciences, Inc. Announces First Patient Successfully Dosed in Phase I Study of Pindnarulex in Combination with Pfizer's Talazoparib for the Treatment of Prostate Cancer	31/22/31	CI
Senhwa Biosciences, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	12/22/12	CI
Senhwa Biosciences, Inc. Pindnarulex in Combination Study with Pfizer's Talazoparib for the Treatment of Prostate Cancer Granted Approval to Initiate from Australian HREC	06/22/06	CI
Senhwa Biosciences, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022	12/22/12	CI
Senhwa Biosciences, Inc. Presents Positive Initial Data from Phase 1 Clinical Trial of Silmitasertib Used to Treat Patients with Advanced Basal Cell Carcinoma at 2022 AAD Annual Meeting	28/22/28	CI
Senhwa Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021	11/22/11	CI
US FDA Grants Fast Track Designation to Senhwa Biosciences' Cancer Drug	26/22/26	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights Senhwa Biosciences, Inc.

Equities

6492

TW0006492002

Highlights

Filters